The Predictive Value of Serum C-Reactive Protein (Crp) Levels in Untreated Prostatic Cancer

  • A. Akdas
  • E. H. Cooper
  • P. H. Smith
  • M. R. G. Robinson
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)


C-reactive protein (CRP) is an acute phase reactant protein (APRP). The APRP’s are a group of mainly glycoproteins which alter their plasma concentrations in response to a variety of stimuli including tissue injury, acute and chronic inflammation, connective tissue disease and cancer (1–3). Most of them are also influenced by oestrogens, which are often employed therapeutically in the management of prostatic cancer. CRP differs from the others in this respect (4). Plasma concentrations are, however, elevated as tumour burden increases (5). This present study evaluates the pre-treatment levels of CRP and serum acid phosphatase (SAP) in patients with benign prostatic hyperplasia and carcinoma of the prostate to determine the prognostic value of these tumour markers in the management of malignant prostatic disease.


Prostate Cancer Benign Prostatic Hyperplasia Connective Tissue Disease Single Radial Immunodiffusion Tumour Burden Increase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    C.L. Fischer and C.W. Gill, Acute Phase Proteins, in “Serum Abnormalities, Diagnostic and Clinical Aspects”, E.S. Ritzman and J.C. Daniels (eds), Little Brown and Co, Boston (1975) p.331.Google Scholar
  2. 2.
    A. Koj, Acute Phase Reactants, Their Synthesis, Turnover and Biological Significance, in “Structure and Function of Plasma Proteins”, A.C. Allison (ed), Plenum Press, London (1974) p.73.CrossRefGoogle Scholar
  3. 3.
    J.A. Owen, Effect of Injury on Plasma Proteins, Advances in Clin. Chem. 9:1 (1967).CrossRefGoogle Scholar
  4. 4.
    A. Milford Ward, E.H. Cooper and A.L. Houghton, Acute Phase Reactant Proteins in Prostatic Cancer, Brit. J. Urol. 49:411 (1977).CrossRefGoogle Scholar
  5. 5.
    J. Kohn, M. Hernandez and P.G. Riches, The Value of Acute Phase Reactants in the Management of the Disease, La Ricerca in Clin-ica e in Laboratorio, 8:61 (1978).Google Scholar
  6. 6.
    G. Mancini, A.O. Carbonara and J.F. Heremans, Immunological Quantitation of Antigens by Single Radial Immunodiffusion, Immunochemistry, 2:235 (1965).PubMedCrossRefGoogle Scholar
  7. 7.
    M.A. Andersch and A.J. Szczypinski, Use of P-Nitrophenyl Phosphate as the Substrate in Determination of Serum Acid Phosphatase, Amer. J. Clin. Pathol. 17:571 (1947).Google Scholar
  8. 8.
    B.W. Brown Jr. and M. Hollander, Censored Data, in “Statistics. A Biomedical Introduction”, B.W. Brown Jr. and M. Hollander (eds) John Wiley and Sons, New York (1977) p. 341.CrossRefGoogle Scholar
  9. 9.
    J.A. Child, E.H. Cooper, S. Illingworth and T.S. Worthy, Biochemical Markers in Hodgkin’s disease and Non-Hodgkin Lymphoma, Recent Results in Cancer Res. 64:180 (1978).CrossRefGoogle Scholar
  10. 10.
    J.R.G. Bastable, B. Richards, S. Howarth and E.H. Cooper, Acute Phase Reactant Proteins in the Management of Carcinoma of the Bladder, Brit. J. Urol. 51:283 (1979).PubMedCrossRefGoogle Scholar
  11. 11.
    E.H. Cooper, Personal Communication (1978).Google Scholar
  12. 12.
    H. Trautner, E.H. Cooper, S. Haworth and A. Milford Ward, An Evaluation of Serum Protein Profiles in the Long Term Surveillance of Prostatic Carcinoma, Scand. J. Urol. 14:143 (1980).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • A. Akdas
    • 1
  • E. H. Cooper
    • 1
  • P. H. Smith
    • 1
  • M. R. G. Robinson
    • 1
  1. 1.Unit for Cancer ResearchUniversity of LeedsUK

Personalised recommendations